Indaptus Therapeutics (NASDAQ:INDP) Stock Price Up 5.2% – Still a Buy?

Indaptus Therapeutics, Inc. (NASDAQ:INDP) rose 5.2% during mid-day trading on Friday . The stock traded as high as $1.2350 and last traded at $1.22. 133,112 shares traded hands during trading, a decline of 85% from the average daily volume of 876,766 shares. The stock had previously closed at $1.16.

Analysts Set New Price Targets

Several equities research analysts have weighed in on INDP shares. Wall Street Zen upgraded shares of Indaptus Therapeutics to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Indaptus Therapeutics Price Performance

The firm has a 50 day moving average price of $1.83 and a 200-day moving average price of $2.12. The firm has a market cap of $162.55 million, a price-to-earnings ratio of -0.19 and a beta of 1.17.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($1.57) by $1.55.

Hedge Funds Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics as of its most recent filing with the Securities and Exchange Commission. 7.06% of the stock is owned by institutional investors.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.